Figures & data
Figure 1 Detailed visual description of the coagulation cascade and the sites blocked either directly or indirectly by old and newer systemic anticoagulants.
Notes: Reprinted with permission Nagarakanti R, Ellis CR. Dabigatran in clinical practice. Clin Ther. 2012;34(10):2051–2060.Citation57
Figure 2 Summary of food and drug interactions with dabigatran.
Note: Reprinted with kind permission from the Springer Science and Business Media.Citation21
Abbreviations: Tmax, time to maximum concentration; Cmax, maximum plasma concentration; AUC, area under the curve; P-gp, P-glycoprotein; AF, atrial fibrillation; CYP3A4, cytochrome P450 3A4; LMWH, low molecular weight heparin; NSAIDs, nonsteroidal anti-inflammatory drugs.
Abbreviations: Tmax, time to maximum concentration; Cmax, maximum plasma concentration; AUC, area under the curve; P-gp, P-glycoprotein; AF, atrial fibrillation; CYP3A4, cytochrome P450 3A4; LMWH, low molecular weight heparin; NSAIDs, nonsteroidal anti-inflammatory drugs.
Figure 3 Responses of various coagulation assays to dabigatran in multiple studies.
Notes: Responses of various coagulation assays to dabigatran in plasma from healthy individuals from single dose (•) and multiple dose studies (○), showing single dose (broken line) and multiple dose (solid line) correlation analysis results. Reprinted with permission Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303. Copyright © 2007 John Wiley and Sons.Citation15
Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio; TT, thrombin time; ECT, Ecarin clotting time.
Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio; TT, thrombin time; ECT, Ecarin clotting time.
Figure 4 Efficacy of two doses of dabigatran in the RE-LY trial.
Notes: Efficacy of two doses of dabigatran (110 mg and 150 mg bid) as cumulative hazard rates for stroke or systemic embolism (the primary outcome) in the Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) trial by treatment. Reprinted with permission Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. Copyright © 2009 Massachusetts Medical Society.Citation25
Figure 5 Kaplan–Meier estimates of survival in the 30 days after an ischemic stroke among patients with NVAF.
Notes: Figure shows Kaplan–Meier estimates of survival in the 30 days after an ischemic stroke among patients with NVAF, according to the antithrombotic-medication status at admission. Patients who were taking warfarin are separated into two groups: those with an INR of less than 2.0, and those with an INR of 2.0 or greater. P-value = 0.002 refers to the overall difference among these groups. From Hylek EM, Go AS, Chang Y. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 349(11):1019–1026. Copyright © 2003 Massachusetts Medical Society. Reprinted with permission by Massachusetts Medical Society.Citation58
Abbreviations: INR, international normalized ratio; NVAF, non-valvular atrial fibrillation.
Abbreviations: INR, international normalized ratio; NVAF, non-valvular atrial fibrillation.
